Online inquiry

IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6425MR)

This product GTTS-WQ6425MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza A infection research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6425MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6009MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CNTO 095
GTTS-WQ3972MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BG9924
GTTS-WQ2833MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG-403
GTTS-WQ277MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ3384MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AT-005
GTTS-WQ13991MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ446MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ12698MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-21M18
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW